J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Daily Mail on MSN

Hope for thousands as new drug cuts prostate cancer relapse risk by a third

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...
Medscape

Time to Relabel Low-Risk Prostate Cancer as Precancerous?

What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade ...
HealthDay on MSN

ASCO: Apalutamide + ADT beneficial in high-risk localized prostate cancer

Perioperative treatment with apalutamide and androgen deprivation therapy (ADT) is beneficial for patients with high-risk ...

New theranostic approach effectively detects and treats neuroendocrine prostate cancer

A novel theranostic approach that targets RET—a newly identified biomarker for neuroendocrine prostate cancer—enables ...
STAT

For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...
NJBIZ

NJ hospitals invest in advanced prostate cancer care

New Jersey hospitals expand prostate cancer treatment with robotics, proton therapy and precision medicine innovations.

GLP-1 drugs may have a beneficial effect across many types of cancer

A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide ...
Labroots

New Immunotherapy Targets Early-Stage Prostate Cancer

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due to its slow growing nature and reduced symptoms. Increased risk factors ...